MBIO News and Press, Mustang Bio Inc. From 05/12/23

2023-05-12 16:16:02 ET Mustang Bio press release ( NASDAQ: MBIO ): Q1 GAAP EPS of -$2.06 beats by $0.95 . As of March 31, 2023, Mustang’s cash and cash equivalents and restricted cash totaled $58.8 million, compared to $76.7 million as of December 31, 2022, a de...

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumo...

Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO)...

2023-04-05 13:14:41 ET Gainers: Nuburu ( BURU ) +83% . Liminal BioSciences ( LMNL ) +80% . InflaRx ( IFRX ) +75% . 180 Life Sciences ( ATNF ) +38% . Freight Technologies ( FRGT ) +25% . Omega Therapeutics ( OMGA ) +23% ...

2023-04-03 14:05:38 ET Mustang Bio ( NASDAQ: MBIO ) announced that it will effect a 15-for-1 reverse stock split of its issued and outstanding common stock. The stock is expected to commence trading on split-adjusted basis on the Nasdaq Capital Market on Apr.4, 2023, after...

WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures fo...

Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or locally advanced cutaneous...

2023-03-29 16:54:05 ET Mustang Bio press release ( NASDAQ: MBIO ): FY GAAP EPS of -$0.75 beats by $0.01 . As of December 31, 2022, Mustang’s cash and cash equivalents and restricted cash totaled $76.7 million, compared to $110.6 million as of December 31, 2021, ...

WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tu...

WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures fo...